留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

2023年中国肝移植临床研究年度盘点

王芳菲, 贺强. 2023年中国肝移植临床研究年度盘点[J]. 器官移植, 2024, 15(3): 377-382. doi: 10.3969/j.issn.1674-7445.2024063
引用本文: 王芳菲, 贺强. 2023年中国肝移植临床研究年度盘点[J]. 器官移植, 2024, 15(3): 377-382. doi: 10.3969/j.issn.1674-7445.2024063
Wang Fangfei, He Qiang. Highlights of clinical research on liver transplantation in China of 2023[J]. ORGAN TRANSPLANTATION, 2024, 15(3): 377-382. doi: 10.3969/j.issn.1674-7445.2024063
Citation: Wang Fangfei, He Qiang. Highlights of clinical research on liver transplantation in China of 2023[J]. ORGAN TRANSPLANTATION, 2024, 15(3): 377-382. doi: 10.3969/j.issn.1674-7445.2024063

2023年中国肝移植临床研究年度盘点

doi: 10.3969/j.issn.1674-7445.2024063
基金项目: 国家自然科学基金(82370665);北京市自然科学基金(7212042、7222303、7232068);北京朝阳医院金种子科研基金(CYJZ202204)
详细信息
    作者简介:
    通讯作者:

    贺强(ORCID 0000-0002-5007-5225),博士,主任医师,研究方向为肝移植与胰腺癌的临床与基础研究,Email: heqiang349@163.com

  • 中图分类号: R617, R575

Highlights of clinical research on liver transplantation in China of 2023

More Information
  • 摘要: 肝移植作为成熟的器官移植手术已成为终末期肝病的最佳治疗手段,提高了患者的生存质量。但目前肝移植依然面临诸多挑战,如排斥反应、感染、胆道并发症、移植物功能恢复延迟、缺血-再灌注损伤、肝细胞癌肝移植术后复发、移植后肾相关疾病、供者短缺等,亟待改善和解决。伴随着我国各位专家学者不断的尝试和经验总结,肝移植相关问题逐年突破。2023年,中国肝移植团队在临床研究领域取得了一系列重大进展,本文就2023年度肝移植临床相关的前沿以及肝移植领域的新技术进展进行综述,总结我国2023年在肝移植领域临床研究取得的成果,以期为促进我国肝移植的进一步发展提供新思路。

     

  • [1] POLLOK JM, TINGUELY P, BERENGUER M, et al. Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference[J]. Lancet Gastroenterol Hepatol, 2023, 8(1): 81-94. DOI: 10.1016/S2468-1253(22)00268-0.
    [2] PINTER M, SCHEINER B, PINATO DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice[J]. Lancet Gastroenterol Hepatol, 2023, 8(8): 760-770. DOI: 10.1016/S2468-1253(23)00147-4.
    [3] WANG SJ, DOUGAN SK, DOUGAN M. Immune mechanisms of toxicity from checkpoint inhibitors[J]. Trends Cancer, 2023, 9(7): 543-553. DOI: 10.1016/j.trecan.2023.04.002.
    [4] SHARMA P, GOSWAMI S, RAYCHAUDHURI D, et al. Immune checkpoint therapy-current perspectives and future directions[J]. Cell, 2023, 186(8): 1652-1669. DOI: 10.1016/j.cell.2023.03.006.
    [5] WANG T, CHEN Z, LIU Y, et al. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss[J]. Liver Transpl, 2023, 29(6): 598-606. DOI: 10.1097/LVT.0000000000000083.
    [6] TU ZH, JIN PB, CHEN DY, et al. Infection evaluation in the early period after liver transplantation: a single-center exploration[J]. Transpl Infect Dis, 2023, 25(2): e14002. DOI: 10.1111/tid.14002.
    [7] UMMAN V, GUMUS T, KIVRATMA HG, et al. Predictive value of red blood cell distribution width, platelet count to lymphocyte count ratio, and neutrophil count to lymphocyte count ratio values for the detection of postoperative infection in patients undergoing liver transplantation[J]. Transplant Proc, 2023, 55(5): 1257-1261. DOI: 10.1016/j.transproceed.2023.05.002.
    [8] LIU M, LI C, LIU J, et al. Risk factors of early bacterial infection and analysis of bacterial composition, distribution and drug susceptibility after cadaveric liver transplantation[J]. Ann Clin Microbiol Antimicrob, 2023, 22(1): 63. DOI: 10.1186/s12941-023-00616-9.
    [9] CHEN C, CHEN B, YANG J, et al. Development and validation of a practical machine learning model to predict sepsis after liver transplantation[J]. Ann Med, 2023, 55(1): 624-633. DOI: 10.1080/07853890.2023.2179104.
    [10] SAKAKIHARA I, KATO H, MURO S, et al. Double-balloon enteroscopy for choledochojejunal anastomotic stenosis after hepato-biliary-pancreatic operation[J]. Dig Endosc, 2015, 27(1): 146-154. DOI: 10.1111/den.12332.
    [11] EGEA VALENZUELA J, JIJÓN CRESPÍN R, SERRANO JIMÉNEZ A, et al. Endoscopic retrograde cholangiopancreatography in the management of biliary complications after orthotopic liver transplantation[J]. Rev Esp Enferm Dig, 2019, 111(12): 909-913. DOI: 10.17235/reed.2019.6284/2019.
    [12] CUI SP, LYU SC, WANG J, et al. Application of cholecystic duct plasty in the prevention of biliary complications following orthotopic liver transplantation[J]. Front Surg, 2023, 10: 1087327. DOI: 10.3389/fsurg.2023.1087327.
    [13] MAURO A, MAZZA S, SCALVINI D, et al. The role of cholangioscopy in biliary diseases[J]. Diagnostics (Basel), 2023, 13(18): 2933. DOI: 10.3390/diagnostics 13182933.
    [14] BOFILL A, CÁRDENAS A. A practical approach to the endoscopic management of biliary strictures after liver transplantation[J]. Ann Hepatol, 2023, 29(2): 101186. DOI: 10.1016/j.aohep.2023.101186.
    [15] ZHANG W, SUN H, DONG D, et al. Safety and feasibility of a novel recanalization technique using guidewire puncture under cholangioscopy for complete biliary stricture after liver transplantation[J]. Sci Rep, 2023, 13(1): 4874. DOI: 10.1038/s41598-023-31475-1.
    [16] LIU J, MAN K. Mechanistic insight and clinical implications of ischemia/reperfusion injury post liver transplantation[J]. Cell Mol Gastroenterol Hepatol, 2023, 15(6): 1463-1474. DOI: 10.1016/j.jcmgh.2023.03.003.
    [17] GAZIA C, LENCI I, MANZIA TM, et al. Current strategies to minimize ischemia-reperfusion injury in liver transplantation: a systematic review[J]. Rev Recent Clin Trials, 2021, 16(4): 372-380. DOI: 10.2174/1574887116666210729112932.
    [18] PENG S, LIANG W, LIU Z, et al. Hypothermic machine perfusion reduces donation after circulatory death liver ischemia-reperfusion injury through the SERPINA3-mediated PI3Kδ/Akt pathway[J]. Hum Cell, 2024, 37(2): 420-434. DOI: 10.1007/s13577-023-01012-3.
    [19] GUO Z, ZHAO Q, JIA Z, et al. A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease[J]. J Hepatol, 2023, 79(2): 394-402. DOI: 10.1016/j.jhep.2023.04.010.
    [20] JIANG J, HUANG H, CHEN R, et al. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?[J]. Front Immunol, 2023, 14: 1092401. DOI: 10.3389/fimmu.2023.1092401.
    [21] IVANICS T, CLAASEN MPAW, SAMSTEIN B, et al. Living donor liver transplantation for hepatocellular carcinoma within and outside traditional selection criteria: a multicentric North American experience[J]. Ann Surg, 2024, 279(1): 104-111. DOI: 10.1097/SLA.0000000000006049.
    [22] LIN CC, CHEN CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes[J]. Hepatobiliary Surg Nutr, 2016, 5(5): 415-421. DOI: 10.21037/hbsn.2016.08.02.
    [23] ZHANG W, BI Y, YANG K, et al. A new model based on gamma-glutamyl transpeptidase to lymphocyte ratio and systemic immune-inflammation index can effectively predict the recurrence of hepatocellular carcinoma after liver transplantation[J]. Front Oncol, 2023, 13: 1178123. DOI: 10.3389/fonc.2023.1178123.
    [24] QU WF, TIAN MX, LU HW, et al. Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation[J]. Hepatol Int, 2023, 17(4): 927-941. DOI: 10.1007/s12072-023-10511-2.
    [25] LAO Q, WU X, ZHENG X, et al. Effect of tacrolimus time in therapeutic range on postoperative recurrence in patients undergoing liver transplantation for liver cancer[J]. Ther Drug Monit, 2024, 46(1): 42-48. DOI: 10.1097/FTD.0000000000001119.
    [26] CUI S, CAO S, CHEN Q, et al. Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation[J]. Front Immunol, 2023, 14: 1118053. DOI: 10.3389/fimmu.2023.1118053.
    [27] WANG J, BAO J, WANG R, et al. The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients[J]. World J Surg Oncol, 2023, 21(1): 104. DOI: 10.1186/s12957-023-02994-y.
    [28] WANG Y, ZHANG W, GE H, et al. Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation[J]. BMC Cancer, 2023, 23(1): 86. DOI: 10.1186/s12885-023-10550-w.
    [29] ZHANG X, CAI L, FANG J, et al. Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Front Oncol, 2023, 12: 1101351. DOI: 10.3389/fonc.2022.1101351.
    [30] YANG J, CHEN Y, SUN H, et al. Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation[J]. Infect Agent Cancer, 2023, 18(1): 2. DOI: 10.1186/s13027-022-00478-4.
    [31] NORÉN Å, MÖLNE J, BENNET W, et al. End-ischemic hypothermic oxygenated machine perfusion does not improve renal outcome following liver transplantation from aged donors: a single-center retrospective report[J]. Artif Organs, 2023, 47(12): 1854-1864. DOI: 10.1111/aor.14640.
    [32] AZPILICUETA-IDARRETA M, PRIETO-TORRE M, MONTIJANO-HERRERO L, et al. Kidney injury associated with liver transplantation[J]. An Pediatr (Engl Ed), 2023, 99(4): 232-239. DOI: 10.1016/j.anpede.2023.08.002.
    [33] LIZAOLA-MAYO B, VARGAS HE. Hepatorenal syndrome-acute kidney injury in liver transplantation[J]. Clin Gastroenterol Hepatol, 2023, 21(10S): S20-S26. DOI: 10.1016/j.cgh.2023.06.010.
    [34] WU Z, WANG Y, HE L, et al. Development of a nomogram for the prediction of acute kidney injury after liver transplantation: a model based on clinical parameters and postoperative cystatin C level[J]. Ann Med, 2023, 55(2): 2259410. DOI: 10.1080/07853890.2023.2259410.
    [35] ZENG J, LI Q, WU Q, et al. A novel online calculator predicting acute kidney injury after liver transplantation: a retrospective study[J]. Transpl Int, 2023, 36: 10887. DOI: 10.3389/ti.2023.10887.
    [36] CABEZA RIVERA FH, CONCEPCION BP, LEVEA SL. Chronic kidney disease after liver transplantation[J]. Adv Kidney Dis Health, 2023, 30(4): 368-377. DOI: 10.1053/j.akdh.2023.07.004.
    [37] HE Z, LIN Y, DONG S, et al. Development and validation of a nomogram model for predicting chronic kidney disease after liver transplantation: a multi-center retrospective study[J]. Sci Rep, 2023, 13(1): 11380. DOI: 10.1038/s41598-023-38626-4.
    [38] LU J, LIN Z, XIONG Y, et al. Performance assessment of medical service for organ transplant department based on diagnosis-related groups: a programme incorporating ischemia-free liver transplantation in China[J]. Front Public Health, 2023, 11: 1092182. DOI: 10.3389/fpubh.2023.1092182.
    [39] GUO Z, ZHAN L, GAO N, et al. Metabolomics differences of the donor livers between in situ and ex situ conditions during ischemia-free liver transplantation[J]. Transplantation, 2023, 107(5): e139-e151. DOI: 10.1097/TP.0000000000004529.
    [40] VIMALESVARAN S, VERMA A, DHAWAN A. Pediatric liver transplantation: selection criteria and post-transplant medical management[J]. Indian J Pediatr, 2024, 91(4): 383-390. DOI: 10.1007/s12098-023-04963-5.
    [41] ELDREDGE JA, HARDIKAR W. Current status and future directions of liver transplantation for metabolic liver disease in children[J]. Pediatr Transplant, 2024, 28(1): e14625. DOI: 10.1111/petr.14625.
    [42] GU GX, PAN ST, FAN YC, et al. Development and validation of a nomogram to predict allograft survival after pediatric liver transplantation[J]. World J Pediatr, 2024, 20(3): 239-249. DOI: 10.1007/s12519-023-00766-y.
    [43] GU G, ZHOU T, ZONG Z, et al. Development of a predictive nomogram for switching immunosuppressive drugs in pediatric liver transplant recipients[J]. Front Pediatr, 2023, 11: 1226816. DOI: 10.3389/fped.2023.1226816.
    [44] XU M, DONG C, SUN C, et al. Impact of donor age on short-term outcomes after pediatric split liver transplantation[J]. Front Pediatr, 2023, 11: 1131629. DOI: 10.3389/fped.2023.1131629.
    [45] PANDYA K, SASTRY V, PANLILIO MT, et al. Differential impact of extended criteria donors after brain death or circulatory death in adult liver transplantation[J]. Liver Transpl, 2020, 26(12): 1603-1617. DOI: 10.1002/lt.25859.
    [46] VODKIN I, KUO A. Extended criteria donors in liver transplantation[J]. Clin Liver Dis, 2017, 21(2): 289-301. DOI: 10.1016/j.cld.2016.12.004.
    [47] DIMOU FM, MEHTA HB, ADHIKARI D, et al. The role of extended criteria donors in liver transplantation for nonalcoholic steatohepatitis[J]. Surgery, 2016, 160(6): 1533-1543. DOI: 10.1016/j.surg.2016.06.051.
    [48] CHEN Z, MA Y, DONG Y, et al. Utilization of hepatitis B surface antigen-positive donors in liver transplantation for recipients with hepatocellular carcinoma: a retrospective and propensity score matching analysis[J]. PeerJ, 2023, 11: e15620. DOI: 10.7717/peerj.15620.
    [49] YANG M, WEI X, KHAN AR, et al. Stratified analysis of survival benefit for ABO-incompatible deceased-donor liver transplantation: multicenter propensity score-matched study[J]. J Clin Transl Hepatol, 2023, 11(4): 827-838. DOI: 10.14218/JCTH.2022.00297.
    [50] DING L, YU X, ZHANG R, et al. Full-right full-left split liver transplantation for two adult recipients: a single-center experience in China[J]. J Clin Med, 2023, 12(11): 3782. DOI: 10.3390/jcm12113782.
    [51] MUHAMMAD I, REHMAN FUL, WANG F, et al. Application effectiveness of segment IV portal vein reconstruction for early postoperative liver function recovery in split liver transplantation[J]. Transpl Int, 2023, 36: 10808. DOI: 10.3389/ti.2023.10808.
  • 加载中
图(1)
计量
  • 文章访问数:  288
  • HTML全文浏览量:  67
  • PDF下载量:  67
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-02-01
  • 网络出版日期:  2024-03-25
  • 刊出日期:  2024-05-07

目录

    /

    返回文章
    返回